ArticleNature protocols2010
A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells.
Article in Nature protocols, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Maintenance of stem cell self-renewal by sex chromosomal zinc-finger transcription factors.World journal of methodology · 2024Article
- Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Immortalizing Mesenchymal Stromal Cells from Aged Donors While Keeping Their Essential Features.Stem cells international · 2020Article
- Stem Cell Therapies for Treatment of Liver Disease.Biomedicines · 2016Review
- A protocol for the identification and validation of novel genetic causes of kidney disease.BMC nephrology · 2015Article
- Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment.Journal of clinical medicine · 2014Review
- Induced pluripotent stem cells in hematology: current and future applications.Blood cancer journal · 2014Review
- The PI3K/Akt1 pathway enhances steady-state levels of FANCL.Molecular biology of the cell · 2013Article
- Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions.Methods in molecular biology (Clifton, N.J.) · 2013Article
- Cyclin A1 is essential for setting the pluripotent state and reducing tumorigenicity of induced pluripotent stem cells.Stem cells and development · 2012Article
- Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk.Stem cells translational medicine · 2012Article
- Reprogramming based gene therapy for inherited red blood cell disorders.Cell research · 2012Article
- Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.EMBO molecular medicine · 2012Article
- Prospect of induced pluripotent stem cell genetic repair to cure genetic diseases.Stem cells international · 2012Article
- Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells.Human gene therapy · 2012Article
- Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector.Nature protocols · 2011Article
- Modeling neurological diseases using patient-derived induced pluripotent stem cells.Future neurology · 2011Article
- A protocol to assess cell cycle and apoptosis in human and mouse pluripotent cells.Cell communication and signaling : CCS · 2011Article
- Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.Cell stem cell · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The generation of patient-specific induced pluripotent stem cells (iPSCs) offers unprecedented opportunities for modeling and treating human disease. In combination with gene therapy, the iPSC technology can be used to generate disease-free progenitor cells of potential interest for autologous cell therapy. We explain a protocol for the reproducible generation of genetically corrected iPSCs starting from the skin biopsies of Fanconi anemia patients using retroviral transduction with OCT4, SOX2 and KLF4. Before reprogramming, the fibroblasts and/or keratinocytes of the patients are genetically corrected with lentiviruses expressing FANCA. The same approach may be used for other diseases susceptible to gene therapy correction. Genetically corrected, characterized lines of patient-specific iPSCs can be obtained in 4-5 months.
Indexed as
Identifiers
20224565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.